Neuro oncology News and Research

RSS

Combination of two targeted drugs shows "clinically meaningful" activity in some malignant brain tumors

A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.

25 Nov 2021

Study sheds light on how residential distance from care impacts cancer diagnosis and survival

In a seemingly counterintuitive finding, young adults diagnosed with central nervous system (CNS) tumors might have better survival rates the farther they live from care.

21 Nov 2021

Study explores the impact of ethnicity on brain tumor survival

White British people who have been diagnosed with a malignant primary brain tumor appear to be more likely to die within one year than patients from at least four other ethnic groups according to a study presented at the NCRI Festival.

9 Nov 2021

Northwestern’s SPORE has made advances in understanding the genetic basis of glioblastoma

Glioblastoma is one of the deadliest cancers known to man. While the advent of immunotherapy and other cutting-edge treatments have prolonged life for people afflicted with other types of cancer, the prognosis for glioblastoma has remained relatively constant: just 18 months.

3 Oct 2021

Long-held theory of cancer-induced immune suppression requires revision, study says

Many cancers produce an enzyme called IDO that suppresses immune system activity, but the long-held hypothesis of how this mechanism operates requires revision, according to a study published in Clinical Cancer Research.

29 Sep 2021

Sex, age are crucial factors in the care and survival of patients with malignant brain tumors

Findings from a national study by researchers at Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and external collaborators suggest that sex and age are crucial factors in the care and survival of patients with malignant brain tumors and other central nervous systems (CNS) cancers.

23 Sep 2021

Rockefeller saliva test turns out to be easier and safer to administer than conventional COVID tests

In the early days of the pandemic, with commercial COVID tests in short supply, Rockefeller's Robert B. Darnell developed an in-house assay to identify positive cases within the Rockefeller community.

16 Sep 2021

Results from Phase 0/1 trial of ribociclib plus everolimus in patients with high-grade glioma announced

The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, announced results from their Phase 0/1 clinical trial of ribociclib plus everolimus in patients with high-grade glioma (HGG).

13 Sep 2021

Study in dogs may lead to better understanding of how gliomas affect the immune system

A new study reveals that high-grade gliomas, or brain tumors, in dogs contained more immune cells associated with suppressing immune response than low-grade gliomas.

20 Aug 2021

New recommendations for diagnosis and treatment of brain metastases from solid tumors

Brain metastases are a common and dangerous complication in cancer patients. Under the leadership of experts from MedUni Vienna, two of the largest international oncology societies have published new clinical guidelines for the diagnosis and treatment of brain metastases from solid tumors.

9 Aug 2021

Gateway for Cancer Research funds EORTC 1634-BTG trial in post-pubertal brain tumor patients

Gateway for Cancer Research℠ awards grant to the EORTC 1634- Brain Tumour Group (BTG) academic trial in Post-Pubertal Patients with Newly-Diagnosed Medulloblastoma (PersoMed-I).

27 Jul 2021

KIYATEC’s test results accurately predict treatment response in recurrent high-grade glioma patients

KIYATEC, Inc. announced today the publication of new peer-reviewed data that establishes clinically meaningful prediction of patient-specific responses to standard of care therapy, prior to treatment, in newly diagnosed glioblastoma (GBM) and other high-grade glioma (HGG) patients.

18 Jun 2021

NFCR announces winners of 2021 Salisbury Award Competition

The National Foundation for Cancer Research (NFCR) announced winners of the 2021 Salisbury Award Competition for Entrepreneurial Translational Research, selected from among eight semi-finalists after pitch presentations in front of a judging committee consisting of prominent cancer research scientists, clinicians, early-stage investors and business leaders.

26 May 2021

Using ultrasound and RNA-loaded nanoparticles to deliver potent medicine to brain tumors

RNA-based drugs have the potential to change the standard of care for many diseases, making personalized medicine a reality. This rapidly expanding class of therapeutics are cost-effective, fairly easy to manufacture, and able to go where no drug has gone before, reaching previously undruggable pathways.

7 May 2021

Research finds possible explanation for why many cancer drugs don't work in human trials

A possible explanation for why many cancer drugs that kill tumor cells in mouse models won't work in human trials has been found by researchers with The University of Texas Health Science Center at Houston (UTHealth) School of Biomedical Informatics and McGovern Medical School.

1 Apr 2021

Giving chemotherapy in the morning can extend survival of glioblastoma patients

An aggressive type of brain cancer, glioblastoma has no cure. Patients survive an average of 15 months after diagnosis, with fewer than 10% of patients surviving longer than five years.

31 Mar 2021

Scientists discover new immunotherapy target for malignant brain tumors

Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body's immune system.

15 Feb 2021

MSK researchers report an underlying cause of COVID brain

One of the dozens of unusual symptoms that have emerged in COVID-19 patients is a condition that's informally called "COVID brain" or "brain fog."

9 Feb 2021

RENACER: New national hospital network aims to advance research on brain metastases

Last January 25th, the bylaws of the National Brain Metastasis Network (or RENACER, its acronym in Spanish) were signed and the network's first meeting was held.

27 Jan 2021

New drug reduces tumor volume and pain in patients with neurofibromatosis type 1

Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children's Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1).

15 Jan 2021